Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.80 |
| ▸ | ADORA1 | P30542 | 12/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326463 | 0.89 | ADORA2A (1.00) | ADORA2AADORA1HTTMEN1ALDH1A1 | |
| SCHEMBL2321435 | 0.88 | ADORA2A (0.80) | ADORA2AADORA1HTTMEN1ALDH1A1 | |
| SCHEMBL2326401 | 0.87 | ADORA2A (0.73) | ADORA2AADORA1HTTMEN1ALDH1A1 | |
| SCHEMBL2320505 | 0.85 | ADORA2A (0.80) | ADORA2AADORA1HTTMEN1ALDH1A1 | |
| SCHEMBL2322526 | 0.85 | ADORA2A (0.80) | ADORA2AADORA1HTTMEN1ALDH1A1 | |
| SCHEMBL2322175 | 0.82 | ADORA2A (0.74) | ADORA2AADORA1MEN1LMNAKMT2A | |
| SCHEMBL2324134 | 0.80 | ADORA2A (0.71) | ADORA2AADORA1MEN1ALDH1A1LMNA | |
| SCHEMBL2323054 | 0.79 | ADORA2A (0.64) | ADORA2AADORA1ALDH1A1MAPTKMT2A | |
| SCHEMBL2321421 | 0.78 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL2322807 | 0.78 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-27 | — | — | US | disclosed |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-10-30 | — | — | US | disclosed |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-06-23 | — | — | US | disclosed |
| EP-2531492-B1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| US-9249130-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-20150005276-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| CN-102822150-B | 1,2, 4-triazin-4-amine derivatives | HEPTARES THERAPEUTICS LTD | 2014-12-03 | — | — | CN | disclosed |
| US-8809525-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-2531492-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | Heptares Therapeutics Limited (GB) | 2012-12-12 | — | — | EP | disclosed |
| CN-102822150-A | 1,2, 4-triazin-4-amine derivatives | HEPTARES THERAPEUTICS LTD | 2012-12-12 | — | — | CN | disclosed |
| WO-2011095625-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005276-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885HTT 1094/4885 |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885HTT 1094/4885 |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885HTT 1094/4885 |
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885HTT 1145/4885 |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885HTT 667/4885 |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885HTT 1067/4885 |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ADORA1 3/4885HTT 1454/4885 |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | PTGER1, LTB4R2, LTB4R | ADORA2A 29/4885ADORA1 19/4885HTT 1492/4885 |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA1 3/4885HTT 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.